Emilio Mantero-Atienza, MD
Psychiatry · Miami Beach, FLNPI 1912014804
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $4,834 of the $6,593 with a category attached, or 73.3%. Sunovion Pharmaceuticals Inc. accounts for 82.8% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2019 at $2,811 and has fallen 94.0% since, to $170 in 2025.
Across 53 payments — averaging $124.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$5K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$453
- Otsuka America Pharmaceutical, Inc.$453
- E.r. Squibb & Sons, L.L.C.$106
- Teva Pharmaceuticals USA, Inc.$43
- C2n Diagnostics, LLC$29
- plus $53 from 3 others
Across 1,635 payments — averaging $6767.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Teva Pharmaceuticals USA, Inc.$2.9M
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1.9M
- Hoffmann-la Roche Limited$1.2M
- E.r. Squibb & Sons, L.L.C.$1.1M
- Otsuka Pharmaceutical Development & Commercialization, Inc.$842K
- Janssen Research & Development, LLC$792K
- plus $2.4M from 23 others
What the payments were for
- Speaking & faculty fees$4,83473%
- Food & beverage$1,75527%
- Education$40%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LATUDA$5,072
- ABILIFY MAINTENA$250
- REXULTI$148
- LONHALA MAGNAIR$111
How this compares
$6,593 in reported general payments places this provider in the 85th percentile of 2,059 psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Chlorpromazine Hcl | 34 | $5,413 |
| Lurasidone Hcl | 27 | $5,337 |
| Memantine Hcl | 71 | $2,987 |
| Acamprosate Calcium | 20 | $1,946 |
| Clozapine | 21 | $1,836 |
| Duloxetine Hcl | 91 | $1,574 |
| Mirtazapine | 125 | $1,390 |
| Clonazepam | 183 | $1,212 |
| Divalproex Sodium | 70 | $1,177 |
| Ziprasidone Hcl | 12 | $852 |
| Bupropion XlBupropion Hcl | 30 | $787 |
| Olanzapine | 61 | $762 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 48 | $617 |
| Oxcarbazepine | 23 | $616 |
| Quetiapine Fumarate | 55 | $574 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Miami Beach
- Andrew CutlerLakewood Ranch$5.7M
- Richard JacksonBoca Raton$3.6M
- Ilan MelnickCoral Gables$2.8M
- Todd BroderSt Augustine$1.6M
- Heather LuingSaint Augustine$1.5M
- Todd GatesWest Melbourne$1.2M
- Lawrence ReccoppaGainesville$968K
- Thomas ValenteLeesburg$967K
- Michelle ScargleClearwater$926K
- David SheehanTampa$631K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.